METHOD OF OPTIMIZING THE TREATMENT OF PROLIFERATIVE DISEASES MEDIATED BY THE TYROSINE KINASE RECEPTOR KIT WITH IMATINIB

The present invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular gastro-intestinal stromal tumors (GIST), in a human patient population.

GIST are uncommon visceral sarcoma that arise predominantly in the gastrointestinal tract. GIST are the most common subtype of Gl sarcomas, which also include leiomyosarcomas, liposarcomas and other more rare histologic subtypes. GIST have been reported to represent about 3 % of all malignant tumours. GIST are most common in the stomach (60 to 70 %), followed by small intestine (20-30 %).

Recent advances in molecular and immuπohistochemical analysis of GIST have identified that GIST cells are positive for CD117, a cell surface antigen localised on the extracellular domain of the trans-membrane tyrosine kinase receptor KIT, the protein of the proto- oncogene c-KIT and receptor for stem cell factor. Upon binding its ligand, stem cell factor, KIT forms a dimer that is autophosphorylated and activates signaling cascades that lead to cell growth. Mutations that lead to an activated form of KIT, especially forms that are activated independently of its ligand, are known and are believed to play a role in certain proliferative diseases, such as mast cell diseases, like mastocytosis, particularly systemic mastocytosis, acute myelogenous leukemia, GIST, sinonasal NK/T-cell lymphoma, seminomas and dysgerminomas. It is hypothesized that virtually all malignant GIST harbour mutations of c- KIT as the driving factor of this disease, resulting in constitutive activation of KIT associated with the signal transduction pathway for cell division and tumour growth. KIT overexpression is determined by immunohistochemistry, which is performed in standard practice.

The present invention relates to a method for minimizing or avoiding the issues of tolerability, lack of efficacy and the risk of relapse in human patients suffering from a proliferative disease mediated by the tyrosine kinase receptor KIT. The invention is based on the finding that the treatment of a proliferative disease, which is mediated by the tyrosine kinase receptor KIT, comprising the administration of a KIT inhibitor or a pharmaceutically acceptable salt thereof to a patient suffering from such proliferative disease can be optimized by adjusting the dose of the KIT inhibitor or a pharmaceutically acceptable salt thereof applied to an indi-

vidual patient in a manner that a specific minimum plasma trough level (Cmin) of the KIT inhibitor is achieved in each single patient. It was found that an individual adjustment for each patient is often required in view of high patient intervariability of the Cmin values after administration of KIT inhibitor to each patient.

The term "proliferative disease mediated by the tyrosine kinase receptor KIT" as used herein should include mast cell diseases, such as mast cell leukemia and systemic mastocytosis, acute myelogenous leukemia (AML), GIST, seminomas, dysgerminomas and metastatic melanoma. The term "proliferative disease mediated by the tyrosine kinase receptor KIT" means especially the proliferative disease systemic mastocytosis, particularly aggressive systemic mastocytosis and GIST, more specifically GIST.

The term "KIT inhibitor" as used herein means a therapeutically active compound such as a small organic molecule or an antibody, which inhibits the activity of the tyrosine kinase receptor KIT, more specifically wild type KIT and certain KIT mutations as defined below. Preferably, the KIT inhibitor inhibits preferably KIT harboring activating mutations.

In one embodiment, the KIT inhibitor employed in the present invention is Imatinib, which has the structure of formula (I),

hereinafter "Compound (I)", or a pharmaceutically acceptable salt thereof. Imatinib is a tyrosine kinase inhibitor that selectively inhibits wild type KIT and certain KIT mutations. In February 2002 the mesylate salt of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2- methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (Imatinib mesylate, STI571 , Glivec®) was approved by the FDA for the treatment of adult patients with CD117 positive unresectable and/or metastatic malignant GIST.

In another embodiment, the KIT inhibitor employed in the present invention is Nilotinib or a pharmaceutically acceptable salt thereof. Nilotinib is a tyrosine kinase inhibitor that selectively inhibits KIT. In 2007 the monohydrochloride monohydrate salt of 4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1 H-imida2θi-1-yl)-3-(trifluoromethyl)- phenyljbenzamide (Nilotinib monohydrochloride monohydrate, Tasigna®), which has the structure (M), hereinafter "Compound (II)",

was approved by the FDA for the treatment of CML for patients who are resistant or intolerant to existing therapies, including treatment with Glivec®. The compound of formula (II) and the process for its manufacture are disclosed in US 7,169,791 , which is hereby incorporated into the present application by reference.

Mutations that lead to an activated form of KIT as referred to herein include, but are not limited to D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561 , N822K, V654A, N822H, Del 550-558 + V654A, Del 557-561 + V654A, lns503AY, V560G, 558NP, Del 557-558, Del W559-560, F522C, Del 579, R634W, K642E, T801 I, C809G, D820Y, N822K, N822H, Y823D, Y823C and T670I.

The present invention provides for the first time an individualized treatment schedule for single patients suffering from a proliferative disease mediated by the tyrosine kinase receptor KIT based on a Cmin lower threshold which was shown to be correlated with an increased overall response (OR) rate and an increased time to progression (TTP).

The term "disease mediated by the tyrosine kinase receptor KIT" as used herein means a disease, wherein KIT is activated by mutations or other molecular mechanisms or overex- pressed, in particular to GIST and systemic mastocytosis, more preferably GIST.

In particular, it was found that patients suffering from GIST having lmatinib levels below about 2050 ng/mL, more specifically, lmatinib levels below about 1 100 ng/mL, show lower OR rate and shorter TTP than patients above that threshold.

As mentioned before, GIST belongs to the group of disease mediated by the tyrosine kinase receptor KIT. The results obtained with the GIST patient population described herein can be transferred directly to the whole group of disease mediated by the tyrosine kinase receptor KIT.

The term "method of treatment" as used herein relates also to a method of prevention of the diseases mentioned herein, i.e. the prophylactic administration of a pharmaceutical composition comprising a KIT inhibitor to healthy patients to prevent the development of the diseases mentioned herein.

The terms "adjusting the dose" and "the dose of ... is adjusted" as used herein preferably denote that the dose referred to is increased or decreased. In a broader sense of the invention, the terms "adjusting the dose" and the "dose of ... is adjusted" encompass a situation wherein the dose remains unchanged.

Hence, in one aspect, the present invention pertains to a method of treating a proliferative disease mediated by the tyrosine kinase receptor KIT, in a human patient comprising the steps of

(a) administering a predetermined fixed amount of lmatinib or a pharmaceutically acceptable salt thereof, e.g. an oral daily dose 400 mg or 600 mg of the monomesylate salt of lmatinib, to the human patient suffering such disease,

(b) collecting at least one blood sample from said patient, e.g. within the first 12 months of treatment, e.g. within the first 30 days,

(c) determining the Cmin of lmatinib, and

(d) adjusting the dose of lmatinib or a pharmaceutically acceptable salt thereof in a manner that a Cmin of at least 1100 ng/mL, preferably a Cmin between 1 100 and about 2500 ng/mL, of lmatinib is achieved in said patient.

In a broader sense, the present invention provides a method of treating a proliferative disease mediated by the tyrosine kinase receptor KIT in a human patient wherein the dose of lmatinib or a pharmaceutically acceptable salt thereof is adjusted in a manner that a Cmin of at least 1100 ng/mL, especially between about 1 100 and about 2500 ng/mL, preferably a Cmin between 2050 and about 2500 ng/mL, of lmatinib is maintained in said patient.

More specifically, the present invention relates to a method of treating GIST in a human patient comprising the steps of

(a) administering a predetermined fixed amount of lmatinib or a pharmaceutically acceptable salt thereof to the human GIST patient in need thereof,

(b) collecting at least one blood sample from said patient, e.g. within the first 12 months, especially the first 3 months, more especially the first 30 days, of treatment,

(c) determining the plasma trough level (Cmin) of lmatinib, and

(d) adjusting the dose of lmatinib or a pharmaceutically acceptable salt thereof in a manner that a Cmin of at least 1100 ng/mL, especially between about 1100 and about 2500 ng/mL, preferably a Cmin between 2050 and about 2500 ng/mL, of lmatinib is achieved in said patient.

In one embodiment of the present invention, the predetermined fixed amount referred to herein under step (a) represents a therapeutically effective amount.

Throughout the present invention, preferably the monomesylate salt of lmatinib is used in step (a), e.g. in an oral daily dose of between about 200 and about 800 mg, preferably in a daily dose of about 400 or 600 mg.

Another important aspect of the present invention is the use of lmatinib or a pharmaceutically acceptable salt thereof, especially lmatinib mesylate, for the manufacture of a medicament for the treatment of GIST, wherein the dose of the pharmaceutically acceptable salt is adjusted in a manner that a Cmin of at least 1100 ng/mL, especially between about 1100 and about 2500 ng/mL, preferably a Cmin between 2050 and about 2500 ng/mL, of lmatinib is maintained in said patient.

The present invention is in particular of benefit for patients with GIST harboring the exon 11 KIT mutation. For the latter sub-population the OOR was 67% for patients with a Cmin below 1100 ng/mL compared to 100 % for patients with a Cmin above 1 100 ng/mL.

The compounds of formula I is specifically disclosed in the patent applications US 5,521 ,184, in particular in Example 21 , the subject-matter of which is hereby incorporated into the present application by reference, lmatinib can also be prepared in accordance with the processes disclosed in WO03/066613.

For the purpose of the present invention, lmatinib is preferably applied in the form of its mono-mesylate salt, lmatinib mono-mesylate can also be prepared in accordance with the processes disclosed in US 6,894,051 the subject-matter of which is hereby incorporated into the present application by reference. Comprised are likewise the corresponding polymorphs, e.g. crystal modifications, which are disclosed therein.

In step (a) of the method described above, in particular a daily dose of between about 200 and about 800 mg, e.g. 400 mg, of the mono-mesylate salt of lmatinib is administered orally, lmatinib mono-mesylate can be administered in dosage forms as described in US 5,521 ,184, US 6,894,051 , US 2005-0267125 or WO2006/121941.

The collecting of a blood sample from patients required under the methods described herein can be accomplished by standard procedures being state of the art. A suitable procedure for the determination of the plasma trough level Cmin of lmatinib and N-{5-[4-(piperazino- methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimi dine-amine was described by R. Bakhtiar R et al. in J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 5;768(2):325-40.

Short Description of the Figures

Fig. 1 depicts the lmatinib trough distribution of the study described in Example 1 (400 mg and 600 mg data combined).

Example 1 : lmatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST)

PURPOSE: In the randomized Phase Il study (B2222), 147 pts with unresectable/metastatic GIST were randomized 1 :1 to receive imatinib (IM) at 400 vs 600 mg daily. Fifty-two (52%) percent of patients are alive for >5 years, regardless of initial dose level. We report the pharmacokinetics (PK) of imatinib (IM) and the relationship between IM levels and clinical response.

METHODS: The IM plasma levels were analyzed in a subset of patients (n=73) for whom PK data on day 1 and at steady state (Day 29) was available (n=34 and 39 for 400 and 600 mg/day, respectively). The effect of patients demographics and blood chemistry parameters on IM PK was evaluated using a population PK approach. A relationship between IM plasma exposure and clinical outcome was explored by grouping patients into quartiles according to IM trough levels (Cmin). The clinical outcome parameters evaluated include overall objective responses (OOR=CR+PR+SD), time to progression (TTP), and KIT mutations.

RESULTS: Population PK analysis showed that patients age, gender, and BW had little effect on imatinib clearance, whereas plasma albumin and WBC counts at baseline were identified as significant covariates. Patients with a higher albumin level or lower WBC counts at baseline appeared to have a higher clearance for IM. Clinical outcomes appeared to be correlated with IM trough exposure. OOR was achieved by 12 of 18 (67%) patients in Q1 (Cmin <1 1 10 πg/mL) compared with 29 of 36 (81 %) and 16 of 19 (84%) in Q2-Q3 (>1110 - <2040 ng/mL), and Q4 (>2040 ng/mL), respectively (p=0.177 for Q1 vs Q2-Q4). The median TTP was 11.3 months for patients in Q1 and over 30 months for Q2-Q4 (p=0.0029). In patients with Exon 1 1 KIT mutations (n=39), the OOR was 67% for Q1 vs 100% for Q2-Q4 (p=0.009). Exon 9 KIT mutation was found in only 12 patients with Cmin data, limiting the power of any correlative analyses in this subset. The IM plasma AUC, peak concentration, and Cmin were highly correlated, with IM Cmin having the best correlation with response.

CONCLUSION: IM demonstrated good oral absorption, but large inter-patient variability in IM exposure. Patients with the lowest IM trough levels (<1100 ng/mL) show lowest OOR rate and shortest TTP.